

**Study of Serum Cystatin C in Relation
to Cardiovascular Morbidity in Type 2
Diabetes Mellitus (Non Insulin
Dependant Diabetes Mellitus) in
Patients without Diabetic
Nephropathy**

Thesis

*Submitted for partial fulfillment of the master degree of degree
in nephrolog*

By:

Mahmoud Fathy Hashem

Diploma of internal medicine

Supervised by

Prof. Dr. Mohamed Ali Ibrahim

Professor of Internal Medicine and Nephrology

"Chair Person of Nephrology Department"

Faculty of Medicine, Ain Shams University

Prof. Dr. Dawlat Hussien Sany

Assistant professor of Internal Medicine and Nephrology

Faculty of Medicine, Ain Shams University

Dr. Essam Nour El-Din Afiffy

Lecturer of Internal Medicine and Nephrology

Faculty of Medicine, Ain shams University

**Faculty of Medicine
Ain Shams University**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية (٣٢)



*First of all, all gratitude is due to **God** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.*

*Really I can hardly find the words to express my gratitude to **Prof. Dr. Mohamed Ali Ibrahim**, Professor of Nephrology and Internal Medicine, "Chair Person of Nephrology Department", Ain Shams University, faculty of Medicine, Ain Shams University, for his supervision, continuous help, encouragement throughout this work and tremendous effort he has done in the meticulous revision of the whole work. It is a great honor to work under his guidance and supervision.*

*I would like also to express my sincere appreciation and gratitude to **Dr. Dawlat Hussien Sany**, Assistant Professor of Internal Medicine and Nephrology, faculty of medicine, Ain Shams University, for her continuous directions and support throughout the whole work.*

*I would also like to express my deep appreciation to **Dr. Essam Nour El-Din Afiffy**, Lecturer of Internal Medicine and Nephrology, Faculty of Medicine-Ain Shams University, for his great kindness, constant assistance and guidance.*

*I am also grateful to **Dr. Yahia Mostafa Mohamed Makkeyah**, Lecturer of Internal Medicine and Nephrology, Faculty of Medicine-Ain Shams University, for his kind effort and support that made achievement of this work possible.*

Last but not least, I dedicate this work to my family, whom without their sincere emotional support, pushing me forward this work would not have ever been completed.

 **Mahmoud Fathy**

Contents

List of Abbreviations	i
List of Tables	ii
List of Fig.s	iii
Introduction and aim of the work.....	v
Review of the literature:	xi
Chapter I: Kidney diseases of diabetes.....	xi
Chapter II: Cystatin C.....	xv
Chapter III: Cystatin C and Cardiovascular Diseases	xv
Patient and methods	vi
Results	xv
Discussion	xv
Summary	xv
Conclusion	xv

Recommendations	١١٨
References	١١٩
Arabic summary	--

List of Abbreviations

ACE	:	Angiotensin-converting enzyme
AGE	:	Advanced glycosylation end products
AKI	:	Acute kidney injury
ARBs	:	Angiotensin receptor blockers
ATN	:	Acute tubular necrosis
BMI	:	Body mass index
BTP	:	B-Trace Protein
C.G	:	Cockcroft and Gault
CBC	:	Complete blood count
CIDP	:	Chronic Inflammatory Demyelinating Polyneuropathy
CKD	:	Chronic kidney disease
CRP	:	C-reactive protein
CSF	:	Cerebrospinal fluid
CTGF	:	Connective tissue growth factor
CVD	:	Cardiovascular Diseases
CyC	:	Cystatin C
DBP	:	Diastolic blood pressure
DK	:	Diabetic ketoacidosis
DKD	:	Diabetic kidney disease
DM	:	Diabetes Mellitus
DN	:	Diabetic nephropathy
DPG	:	Diphosphoglycerate
ERFD	:	Early renal function decline
ERK	:	Extracellular regulating kinase
ESRD	:	End-stage renal disease

List of Abbreviations (Cont.)

ET- γ	: Endothelin- γ
GBM	: Glomerular basement membrane
GBS	: Guillan-Barre Syndrome
GFR	: Glomerular filtration rate
GGT	: γ -glutamyltransferase
GST	: Glutathione S-transferase
HbA γ c	: Glycosylated hemoglobin
HCC	: Human Cystatin C
HDL	: High density lipoprotein
HPLC	: High performance liquid chromatography
HSPG	: Heparan sulfate proteoglycan
IDDM	: Insulin dependent diabetes mellitus
IFKF	: International Federation of Kidney Foundations
IGF	: Insulin-like growth factor
IN	: Immunonephelometry
IND	: Inflammatory Neurologic Diseases
IT	: Immunoturbidimetry
LDH	: Lactate dehydrogenase
LDL	: Low density lipoprotein
MDRD	: Modified Diet in Renal Disease
NADPH	: Nicotinamide adenine dinucleotide phosphate
NAG.	: N-acetyl- β -D-glucosaminidase
NIDDM	: Non insulin dependent diabetes mellitus
OR	: Odds ratio
PA	: Plasminogen activator

List of Abbreviations (Cont.)

PENIA	: Particle-enhanced nephelometric immunoassay
PETIA	: Particle-enhanced turbidimetric immunoassay
PKC	: Protein kinase C
PPAR	: Peroxisome proliferator-activated receptor
RAS	: Renin-angiotensin system
RIA	: Radioimmunoassay
ROS	: Reactive oxygen specie
RPF	: Renal plasma flow
RPN	: Renal papillary necrosis
RRT	: Renal replacement therapy
SBP	: Systolic blood pressure
SNPs	: Single nucleotide polymorphisms
T ¹ D	: Type 1 diabetes
T ² D	: Type 2 diabetes
TGF- β	: Transforming growth factor- β
TNF- α	: Tumor necrosis factor- α
UAE	: Urinary albumin excretion
UTI	: Urinary tract infection
VEGF	: Vascular endothelial growth factor

List of tables

<i>Table</i>	<i>Title</i>	<i>Page</i>
١	Diabetic nephropathy stages based on urinary albumin excretion	١٣
٢	Chronic kidney disease stages	١٧
٣	Treatment of hyperglycemia in the patient with type ٢ diabetes mellitus and chronic kidney disease	٣٣
٤	The human cystatin super family	٤١
٥	Age and disease duration comparison between studied group	٨٢
٦	Sex comparison between studied group	٨٣
٧	Characteristics of the comparison between studied group regarding Clinical data (Weight, Height, BMI, Systolic BP Diastolic BP and Mean arterial BP).	٨٤
٨	Comparison between the three studied groups regarding fasting blood sugar (FBS) and HbA ^{1c}	٨٥
٩	Comparison between the three studied groups regarding lipid profile.	٨٧
١٠	Comparison between the three studied groups regarding kidney functions.	٨٨
١١	Comparison between the three studied groups regarding complete blood picture and liver enzyme.	٨٨
١٢	Comparison between the three studied groups regarding Serum cysteine c and CRP.	٨٩
١٣	Comparison of calculated Cr. Clearance by Cockcroft-Gault formula and estimated GFR by Larsson, s formula	٩٠

	between studied group.	
--	------------------------	--

-iv-

List of tables (Cont.)

<i>Table</i>	<i>Title</i>	<i>Page</i>
١٤	Correlations between different studied parameters with cystatin C and CRP in group I (patients with CVD).	٩٢
١٥	Correlations between different studied parameters with cystatin C and CRP in group II (patients without CVD).	٩٤
١٦	Correlations between different studied parameters with cystatin C and CRP in control group.	٩٥
١٧	Correlations between different studied parameters with cystatin C and CRP in All diabetic cases (positive and negative groups).	٩٦
١٨	Correlations between different studied parameters with eGFR by Larsson Formula and Calculated Cr. Clearance by Cockcroft Gault Formula in All diabetic cases (positive and negative groups).	٩٧
١٩	Correlations between different studied parameters with eGFR by Larsson Formul and Calculated Cr Clearance by Cockcroft Gault Formula in control group.	٩٨
٢٠	Multivariate analysis of prediction for serum cystatin C.	٩٩

List of Figures

<i>Fig.</i>	<i>Title</i>	<i>Page</i>
١	Amino acid sequence and schematic structure of human cystatin C	٤٢
٢	Primary, secondary, tertiary and quaternary structure of HCC.(Adapted from.	٤٤
٣	Molar concentrations of cystatins and α_2 -macroglobulin in ten human body fluids.	٤٥
٤	Proposed mechanisms linking renal dysfunction, inflammation, atherogenesis, and cardiovascular events	٧٢
٥	Mean Age among studied groups.	٨٣
٦	Mean weight among studied groups	٨٤
٧	Mean HbA ^{1c} among studied groups.	٨٥
٨	Mean RBS among studied groups.	٨٦
٩	Comparison of serum cystatin C between the studied groups.	٨٩
١٠	Comparison of CRP among studied groups.	٩٠
١١	Group According to GFR among studied groups.	٩١

Introduction

Diabetes mellitus is one of the most important health issues facing the world in the 21st century. Many of the complications of diabetes are cardiovascular in nature. Patients with type 2 and prediabetics are at risk of developing macrovascular and microvascular complications including: atherosclerosis, coronary heart disease, cardiomyopathy, cerebrovascular stroke, transient ischemic attacks, peripheral neuritis, renal failure, retinopathy and peripheral vascular insufficiency (**Hanefeld M, 2007**).

Cardiovascular risks increase among patient with chronic kidney disease (**Go as et al, 2004**). Patients with chronic kidney disease (CKD), irrespective of diagnosis are at increased risk of cardiovascular disease (CVD), including coronary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure.

Since inflammation plays an important role in atherogenesis and development of cardiovascular disease, C-reactive protein (CRP) has been intensively investigated as potential marker of atherosclerosis and cardiovascular morbidity. However, its role in clinical setting is still debated (**Pinon P and Carlos J, 2006**).

Cystatin C is a non-glycosylated basic protease inhibitor that is produced at a constant rate by all nucleated cells. It is freely filtered by the renal glomerulus and primarily catabolized in the renal tubules (**Newman DJ, 2002**). Levels are reported to be independent of gender, age, and body mass. The serum concentration of cystatin C has recently been proposed as an endogenous marker of renal function that is more reliable than serum creatinine and accurate even at the low concentrations found whether glomerular filtration rate (GFR) is normal or elevated (**Pucci L et al, 2007**).

There is growing evidence suggesting that increased cystatin C concentrations are strongly and independently associated with future cardiovascular events in individuals with high risk. Whether this is exclusively related to cystatin C's ability to accurately assess renal function or is influenced by other factors that may modulate the level of this protein in blood is still a matter of controversy (**Bard JM et al, 2006**).

Aim of the Work

Is to study the possible value of serum cystatin C level as predictor of cardiovascular risks and morbidity in type, ٢ diabetes mellitus in patients without diabetic nephropathy.

Chapter 1

Kidney Diseases of Diabetes

Chronic kidney disease (CKD) is an international public health problem affecting 5% to 10% of the world population (**KDIGO, 2012**). Diabetes mellitus (DM) causes CKD and accelerates its progression, and is recognized as the leading cause of end-stage kidney disease (ESKD) (**Kasper and Harrison 2010; KDOQI, 2012; Toto, 2012**).

CKD associated with DM, often called diabetic kidney disease (DKD), occurs in 30% to 40% of type 1 diabetic patients and in an increasing percentage (up to 20%) of type 2 patients (**Ritz et al., 1999**). The percentage of people with DKD has increased more than for any other cause of CKD, increasing by 10% per year over the last decade (**Collins et al., 2010; Ritz et al., 1999**) and the increase is predominantly in those with type 2 diabetes. The population of existing patients whose ESKD was caused by diabetes (tripled from 1990 to 2000) is expected to grow 10-fold by 2030, to 1.3 million (**Collins et al., 2010**).

In the USA, diabetes now accounts for 40% of prevalent kidney failure, up from 18% in 1980 (**KDOQI, 2012**). DM and CKD are common and exhibit synergistic associations with premature mortality in the general population (**Middleton et al., 2011**).